Evidence map›Paper›PMID 37409813›Full record

ArticlemBio2023

CryoEM analysis of the essential native UDP-glucose pyrophosphorylase from

Xu Han, Cecilia D'Angelo, Ainara Otamendi, Javier O Cifuente, Elisa de Astigarraga, Borja Ochoa-Lizarralde, Martin Grininger, Francoise H Routier, Marcelo E Guerin, Jana Fuehring and 2 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Cascading damage toProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Functional and molecular characterization ofJournal of medical microbiology · 2026
    Article
  3. First genome report ofFrontiers in fungal biology · 2026
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Xu Han *Structural Biology of Cellular Machines Laboratory, Biocruces Bizkaia Health Research Institute, Cruces University Hospital , Barakaldo, Bizkaia, Spain.
Cecilia D'Angelo *Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA) , Derio, Spain.
Ainara OtamendiLaboratory of Biology, Department of Applied Chemistry, Faculty of Chemistry, University of the Basque Country, UPV/EHU , San Sebastian, Spain.
Javier O CifuenteCenter for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA) , Derio, Spain.
Elisa de AstigarragaStructural Biology of Cellular Machines Laboratory, Biocruces Bizkaia Health Research Institute, Cruces University Hospital , Barakaldo, Bizkaia, Spain.
Borja Ochoa-LizarraldeStructural Biology of Cellular Machines Laboratory, Biocruces Bizkaia Health Research Institute, Cruces University Hospital , Barakaldo, Bizkaia, Spain.
Martin GriningerInstitute of Organic Chemistry and Chemical Biology, Buchmann Institute for Molecular Life Sciences, Goethe University Frankfurt , Frankfurt am Main, Germany.
Francoise H RoutierInstitute for Clinical Biochemistry, Hannover Medical School , Hannover, Germany.ORCID 0000-0002-7163-0590
Marcelo E GuerinCenter for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA) , Derio, Spain.
Jana FuehringInstitute for Clinical Biochemistry, Hannover Medical School , Hannover, Germany.ORCID 0000-0001-7174-0442
Oier EtxebesteLaboratory of Biology, Department of Applied Chemistry, Faculty of Chemistry, University of the Basque Country, UPV/EHU , San Sebastian, Spain.ORCID 0000-0002-9786-6091
Sean R ConnellStructural Biology of Cellular Machines Laboratory, Biocruces Bizkaia Health Research Institute, Cruces University Hospital , Barakaldo, Bizkaia, Spain.ORCID 0000-0001-7807-7049
BioCruces Health research Institute · ESIkerbasque · ESMedizinische Hochschule Hannover · DEUniversity of the Basque Country · ESGoethe University Frankfurt · DE

Funding

Rationalizing glycoengineering strategies for immunotherapeutic antibodiesR01AI149297 · NIAID · EMORY UNIVERSITY · PI JEFFREY Victor RAVETCH, ERIC JOHN SUNDBERG · 2020 to 2026
$3.7M
Basque Government IT1662-22Basque Government KK-2019/00076Basque Government KK-2021-00034Basque Government KK-2022/00107Basque Government PIBA-2020-1-0032-GVB0HHS | National Institutes of Health (NIH) R01AI149297Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España (MINECO) CTQ201782222-RMinisterio de Asuntos Económicos y Transformación Digital, Gobierno de España (MINECO) PID2019-105649RB-I00Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España (MINECO) PID2021-122705OB-I00
6 · The paper itself

Abstract

Invasive aspergillosis is one of the most serious clinical invasive fungal infections, resulting in a high case fatality rate among immunocompromised patients. The disease is caused by saprophytic molds in the genus

Indexed as

Aspergillus nidulansFungal ProteinsUTP-Glucose-1-Phosphate UridylyltransferaseCell WallCryoelectron MicroscopyModels, MolecularProtein ConformationUridine Diphosphate GlucoseFungal ProteinsUridine Diphosphate GlucoseUTP-Glucose-1-Phosphate Uridylyltransferaseaspergillosiscell wall biosynthesiscryoEMenzyme mechanismenzyme specificityUDP-glucose pyrophosphorylases

Identifiers

PMID37409813
PMCPMC10470519
OpenAlexW4383302053

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.